Argus downgraded Centene (CNC) to Hold from Buy. Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.

In a report released today, Andrew Mok CFA from Barclays maintained a Buy rating on Centene (CNC – Research Report), with a price target of $93.00. The company’s shares closed yesterday at $61.29.

Centene reported $3.3 billion in 2024 profits as Obamacare enrollment and premium revenue helped ... [+] overcome a big dip in Medicaid enrollment. In this photo, the building housing Centene ...

On Tuesday, Centene touted healthy membership growth in Affordable Care Act plans, while arguing that Medicaid and Medicare — businesses that proved rocky last year — will stabilize in 2025.

Shares of Centene (NYSE:CNC) slipped 4% Tuesday after the healthcare plan provider, which specializes in Medicaid services, issued its Q4 earnings report and 2025 forecast. For Q4, Centene (NYSE ...

In this article, we are going to take a look at where Centene Corporation (NYSE:CNC) stands against the other stocks. Wall Street’s main indices all finished in the green territory on Tuesday ...

Feb 4 (Reuters) - Centene's (CNC.N), opens new tab shares fell nearly 5% on Tuesday hurt by elevated costs tied to its government-backed Medicaid plans, overshadowing a better-than-expected ...

Centene Corporation reported $283 million in profit for the fourth quarter of 2024, a notable bump from the fourth quarter of 2023's haul of $45 million. The earnings performance surpassed Wall ...

Centene Corporation (CNC), a leading multinational healthcare enterprise, is dedicated to providing high-quality, cost-effective healthcare solutions to individuals and families across the United ...